Exchange: NASDAQ·Updated 04:01 AM EDT
JAZZ logo

JAZZJazz Pharmaceuticals plc

$248.50
$0.25
(0.10%)
Pre-Market
Prev Close $248.25
EarningsAug 4
Mkt Cap$15.56B
Vol6.00
News
all
press releases
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Zacks
News Placeholder
More News
News Placeholder
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.
Zacks
News Placeholder
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
Zacks
News Placeholder
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
Zacks
News Placeholder
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
Key PointsZepzelca's failed trial doesn't derail Jazz's growth strategy...
Nasdaq News: Markets
News Placeholder
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Zacks
News Placeholder
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCelleras antibody...
Business Wire
News Placeholder
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.